Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools

Related Articles
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…April 18, 2021
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…June 15, 2025


